hazard prediction and risk assessment, how could they possibly be adequate for chemicals such as pesticides and industrial chemicals, where human exposure is inadvertent and levels of exposure cannot be known?
One of the reasons for setting up FRAME in 1969 was that the Founder Trustees did not believe that reliance on tests in laboratory animals was an acceptable basis for evaluating the safety of drugs intended for use in humans. An early FRAME publicity leaflet, How safe is your medication?, 4 put it like this: "Despite these exhaustive studies [in animals], toxic effects in humans are not revealed until sometime after the drug has been clinically tested… when the drug is finally given to man, he too becomes a 'guinea-pig'."
However, it was decades before it came to be widely accepted that data from animal studies fail to provide sufficiently relevant and reliable guidance on likely toxicity, ahead of the entry of new drugs into clinical trials. Drug attrition has increased significantly, to the point where about 95% of all the drugs that survive the regulatory preclinical testing procedures, fail in clinical trials. This is mostly due to unforeseen toxicities; half of those that do survive, subsequently have to be withdrawn or re-labelled, due to lack of efficacy or adverse drug reactions not detected in animal tests. 5 One recent study showed that 63% of human adverse drug reactions had no counterparts in animals, and that less than 20% had a positive equivalent in animal studies. 6 There is a scientific reason for this: among several notable species differences which confound the extrapolation of data from laboratory animals to humans, there are major differences between humans and other mammals, in, for example, the intestinal absorption of drugs, and in the most important enzymes (CYPs) involved in drug metabolism. Since absorption and distribution, together with metabolism and excretion (ADME), are key aspects of the interaction of drugs with patients, the unchallengeable conclusion must be that animals cannot be good ADME models for humans. This leads to the further conclusion that the continuing and significant extent of the use of animals in preclinical testing cannot be considered to be either necessary or ethically acceptable. In addition, the problem of inter-species differences is likely to be amplified by intra-species differences, since, just as there are no such things as standard human beings, there are no such things as standard mice, rats, rabbits, dogs or macaques. Recognition of this truth is vital as we move toward personalised medicine, which takes human variation into account and replaces the former 'one-drug-suits-all' paradigm.
The fundamental problem was spelled out in 2014, in an article entitled Lost in translation: Animal models and clinical trials in cancer treatment: 7 "The average rate of successful translation from animal models to clinical cancer trials is less than 8%. Animal models are limited in their ability to mimic the extremely complex process of human carcinogenesis, physiology and progression. Therefore, the safety and efficacy identified in animal studies is generally not translated to human trials. …alternative translational approaches have emerged that may eventually replace the link between in vitro studies and clinical applications."
The need to fundamentally reappraise the value of animal studies as an essential and required background to human studies had earlier been emphasised by the US Food and Drug Administration, 8 and the collaborative work of the European Innovative Medicines Initiative 9 affords further grounds for hope. Nevertheless, there continues to be a great desire to maintain established practices and to avoid the evidence which strongly indicates the need for changes in attitudes and activities. For example, we are having great difficulty in persuading government, science and industry to take serious consideration of the outcome of our studies on more than 3000 drugs with both animal and human data, which suggest that the absence of toxicity in animals provides virtually no evidential weight that adverse drug reactions will also be absent in humans. 10 Perhaps a clue to the reason for this can be found in a leaflet entitled, Why research using animals can help defeat dementia, published by Alzheimer's Research UK 11 and used to publicise the 2014 launch of the Concordat on Openness on Animal Research. 12 The leaflet claims that "Research using animals such as mice, rats, worms and fruit flies has underpinned many of the advances made to date", and goes on to emphasise support for the Three Rs (Replacement, Refinement and Reduction). Further insight is given by Understanding Animal Research, in a statement on Alzheimer's Disease, 13 which says that "Although the exact causes of Alzheimer's remain unknown, monkeys and GM mice with Alzheimer's-like brain abnormalities are helping scientists to unlock the secrets of the disease. These animals have been crucial in identifying molecules such as miR-34c that appear to play a role in disease development, and genetic mutations that confer susceptibility to Alzheimer's." How ever, miR-34c plays many other roles and its role in Alzheimer's remains unknown, so it is likely that this emphasis will be as unproductive as the focus on amyloid and tau in the causation of Alzheimer's.
The sad, but inescapable, truth is that, despite all the effort and expenditure of human resources and research funding, very little is known about Alzheimer's disease and why and how it develops, and there is little firm evidence that studies on the animal models are actually of much use at all. As Maria Burke pointed out in 2014, 14 "Dementia has become a graveyard for a large number of promising drugs. A recent study looked at how 244 compounds in 413 clinical trials fared for Alzheimer's diseases between 2002 and 2012. Of these 244 compounds, only one was approved. …this gives Alzheimer's disease drug candidates one of the highest failures rates of any disease area -99.6%, compared with 81% for cancer." Despite the enormous costs of drug discovery, drug development and clinical trials, the failure of Alzheimer's drug candidates continues. 15, 16 The use of animal models will have been central to the preclinical evaluation of all these compounds.
As a result of personal experience, we are deeply concerned for those who suffer, directly or indirectly, from dementia, and have faith that research will eventually provide the solution to the problem. We also appreciate the devotion and efforts of those who raise funds in support of the charities which commission such research. However, merely stating a commitment to the Three Rs is not enough. It must also involve a recognition of the inadequacy of animal models, and investment in the clinical research and non-animal approaches that should replace them.
The sincerity of all those involved should be judged according to the revealed preference theory, which indicates that, while assuming that a set of alternatives have been considered before a decision is made, the actual meaning of any pre-stated choices will be revealed by the choices that are actually made. 17 In other words, it is not what people say that matters, it is what they actually do. Here in the UK, despite all the public statements about commitment to the Three Rs, and especially to replacement, the Home Office statistics reveal that the numbers of animal procedures performed each year remain at a high level -this reveals the truth that many members of the biomedical research community in the UK prefer to use laboratory animal procedures, rather than face up to the difficult challenge of finding human-focused, relevant and reliable replacement procedures.
One way forward would be for the Alliance for Human Relevant Science to campaign to replace the reliance of the medical research charities on experts who are biased in favour of current hypotheses that are derived from their preferred animal-based practices, with experts in clinical research that is based on in vitro and in silico strategies who have a different philosophy and new ideas to offer. We would be interested in knowing what Alzheimer 
